ClinicaliQ Trial Snapshot
- A Study of TYRA-300 in Children With Achondroplasia: BEACH301 — Recruiting • Phase II • NCT06842355.
- TYRA-300 trial tests safety and effective doses of a new treatment for children with achondroplasia who still have growing bones.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, tolerability, and identify potentially effective dose(s) of TYRA-300 in children with achondroplasia with open growth plates. Conditions: Achondroplasia Interventions: TYRA-300 0.125 mg/kg, TYRA-300 0.25 mg/kg, TYRA-300 0.375 mg/kg, TYRA-300 0.50 mg/kg, TYRA-300 0.625 mg/kg Lead Sponsor: Tyra Biosciences, Inc Planned Enrollment: 92 participants